Fibrocystic Breast Diagnostics and Treatment Market Shows A Rapid Growth

Market Overview

The worldwide fibrocystic breasts diagnostics and treatment market is estimated to record a substantial growth over the forecast period (2018–2023).

The fibrocystic breast disease is a non-cancerous ailment. Fibrocystic breasts feel lumpy and is often painful. The lumps are caused due to fibrocystic changes. The lumps form pertaining to the assemblage of fibrous tissues at a portion of the breast. The scar and ligament tissues are built up of fibrous tissue. The transformation in breast tissue is caused by the changing hormone levels experienced by the ovaries resulting in the development of fibrocystic breasts. The changes appear to be troublesome and leads to painful breast lumps and breast swelling. It mainly occurs in women who are close to their perimenopause and menopause, mostly aged between their 30s and 50s. Prevalence of fibrocystic breast disease increases the risk of breast cancer.

Request Sample Copy:

https://www.marketresearchfuture.com/sample_request/6448

Growing rates of breast cancer and rising awareness on breast cancer monitoring programs are likely to drive the market growth. Moreover, the emergence of advanced and minimally invasive breast biopsy equipment is likely to bring up lucrative opportunities in the untapped market. Nevertheless, factors such as infection risks connected with breast biopsy procedures, ambiguous reimbursement policies, and stringent government regulations play a major role in restricting the market growth. Some more constraints for the market include the risk associated with the complex surgical procedures and its high cost. These factors are likely to influence the global fibrocystic breasts diagnostics and treatment market negatively.

Market Segmentation

The worldwide fibrocystic breasts diagnostics and treatment market has been segmented based on end users and type. Based on type, the market has been segmented as treatment and diagnosis. Treatment is sub-segmented into fine-needle aspiration, medications, oral contraceptives, and surgical excision. The medications are further segmented into nonsteroidal anti-inflammatory drugs and acetaminophen. As per end users, the market has been segmented into hospitals, clinics, diagnostic centers, specialty clinics and rehab centers, research institutes, and others. Diagnosis is sub-segmented into breast biopsy and mammogram. 

Regional Analysis

The Americas is likely to lead the fibrocystic breasts diagnostics and treatment market over the forecast period. Increasing rate of surgeries owing to rising healthcare awareness, medical tourism, surge in disposable income, and advancement in technology, are the other factors that influence the fibrocystic breasts diagnostics and treatment market.

Many women, almost more than 90% have disturbed progesterone and estrogen levels in some form. The National Institute of Mental Health (NIMH) reports that disturbances in estrogen levels in women, trigger abnormal functioning of the vital brain memory circuit. Brain scans discovered transformed circuit activity which is linked directly to alterations in the sex hormone in women while women are performing a memory task.

In 2018, Asia-Pacific had been anticipated to be the fastest growing market for fibrocystic breast diagnostics and treatment globally. The market is likely to experience growth attributing to the changing lifestyle and increasing elderly population. Additionally, emergence of advanced treatment facilities, better adoption rate, growing demand for innovative technology, surging rate of government initiatives and increasing healthcare investments, pave the way for improvement in the fibrocystic breasts diagnostics and treatment market.

Key Players

Global fibrocystic breast diagnostics and treatment market has key players such as Boston Scientific, Argon Medical Devices, C. R. Bard, Inc, CareFusion Corporation (Acquired by Becton, Dickinson and Company), Devicor Medical Products Inc., Cook Medical, INRAD, Inc., Allergan plc, Teva Pharmaceutical Industries Ltd, Hologic, Inc., Bayer AG, Merck & Co., Inc., Pfizer Inc., and Gallini Medical Devices.

Browse Complete Report with TOC at

https://www.marketresearchfuture.com/reports/fibrocystic-breasts-diagnostics-treatment-market-6448

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]

Be the first to comment

Please check your e-mail for a link to activate your account.

connect